clinical trial · NCT05665387
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
Presbyopia0.1% STN1013600 ophthalmic solution0.3% STN1013600 ophthalmic solutionPlacebo
brief summary
This is a Phase IIa study to assess efficacy and safety of STN1013600 ophthalmic solution (0.1%, and 0.3 %), twice daily when compared to Placebo in subjects diagnosed with presbyopia. This study will consist of a Screening Period of up to 15 days followed by a 2 Month Treatment Period. After the Treatment Period subjects will be followed for a one-month treatment free period.
started
Dec 22, 2022
primary completion
Jul 27, 2023
completion
Jul 27, 2023
last updated
May 29, 2024
official title
OPSIS: A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol